A 12-Month Multicentre, Randomised, Double-Blind, Placebo-Controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.

Trial Profile

A 12-Month Multicentre, Randomised, Double-Blind, Placebo-Controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Acronyms RIALTO
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual patient number (174) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Additional trial acronym RIALTO identified as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top